最新研究表明，帶狀皰疹疫苗能顯著降低晚年罹患失智症或輕度認知衰退的人數 ；俄羅斯正在研發多種治療性癌症疫苗，其中最引人注目的是一種基於mRNA的疫苗和一種名為Enteromix的溶瘤病毒疫苗。這些治療性疫苗旨在透過訓練免疫系統識別並摧毀腫瘤細胞來治療現有癌症；狀態：這些疫苗已完成臨床前試驗，研發人員聲稱在縮小腫瘤方面具有很高的療效（據報道，在動物模型中有效率達60-80%）。 臨床試驗：Enteromix的小規模人體I期試驗（涉及48名志願者）於2025年6月左右啟動，主要針對大腸直腸癌，並計畫擴展到黑色素瘤和膠質母細胞瘤。.....

 

最新研究表明，帶狀皰疹疫苗能顯著降低晚年罹患失智症或輕度認知衰退的人數 https://econ.st/4s73gdz

The Economis

New research points to the shingles vaccine meaningfully reducing the number of people who develop either dementia or mild cognitive decline later in life https://econ.st/4s73gdz

人工智慧概述

俄羅斯正在研發多種治療性癌症疫苗，其中最引人注目的是一種基於mRNA的疫苗和一種名為Enteromix的溶瘤病毒疫苗。這些治療性疫苗旨在透過訓練免疫系統識別並摧毀腫瘤細胞來治療現有癌症，而不是預防癌症的初始發展。

截至2026年初的關鍵訊息：

狀態：這些疫苗已完成臨床前試驗，研發人員聲稱在縮小腫瘤方面具有很高的療效（據報道，在動物模型中有效率達60-80%）。

臨床試驗：Enteromix的小規模人體I期試驗（涉及48名志願者）於2025年6月左右啟動，主要針對大腸直腸癌，並計畫擴展到黑色素瘤和膠質母細胞瘤。

可用性：2025年底，官方報告稱該疫苗“已準備就緒”，正在等待最終監管部門的批准，以便在俄羅斯更廣泛地應用。

機制：這些是個人化疫苗。分析患者的腫瘤樣本以識別獨特的抗原，並客製化疫苗來訓練T細胞攻擊特定的癌症。

安全性和成本：早期報告顯示，與化療相比，該疫苗安全性良好，副作用極小，政府已宣布計劃向公民免費提供。

科學和醫學背景：

並非“萬能藥”：研究人員和獨立專家強調，這並非一種通用的“癌症療法”，而是一種標靶療法。

缺乏同儕審查：截至2025年底，大規模III期人體臨床試驗數據及經同儕審查的已發表結果有限，導致國際醫學界對此持謹慎態度。

比較：這些研究與全球其他個人化mRNA癌症疫苗研究（例如Moderna/Merck）類似，但特別著重在俄羅斯快速、免費、國家資助的推廣。

結論：俄羅斯癌症疫苗計畫（Enteromix）處於臨床開發的早期至中期階段，早期試驗顯示出前景，但仍需進一步驗證，以確定其長期安全性和有效性，目前正在進行相關驗證。

AI Overview

Russia is developing several therapeutic cancer vaccines, most notably 

an mRNA-based vaccine and an oncolytic virus vaccine known as Enteromix. These are therapeutic vaccines designed to treat existing cancers by training the immune system to recognize and destroy tumor cells, rather than preventing the initial development of cancer. 

Key Information as of Early 2026:

• Status: The vaccines have completed preclinical trials, with developers claiming high efficacy in shrinking tumors (reported 60–80% effectiveness in animal models).
• Clinical Trials: Small-scale human Phase I trials (involving 48 volunteers) for Enteromix began around June 2025, focusing on colorectal cancer, with plans to expand to melanoma and glioblastoma.
• Availability: In late 2025, officials reported the vaccine was "ready for use" and awaiting final regulatory approval for broader application in Russia.
• Mechanism: These are personalized vaccines. A patient's tumor sample is analyzed to identify unique antigens, and a custom vaccine is produced to train T-cells to attack that specific cancer.
• Safety and Cost: Early reports suggest a good safety profile with minimal side effects compared to chemotherapy, and the government has announced plans to provide it free to citizens. 

Scientific and Medical Context:

• Not a "Cure-All": Researchers and independent experts emphasize that this is not a universal "cure for cancer" but a targeted therapy.
• Lack of Peer Review: As of late 2025, large-scale Phase III human clinical trial data and peer-reviewed, published results are limited, leading to caution from the international medical community.
• Comparison: These efforts are similar to other personalized mRNA cancer vaccine research worldwide (e.g., Moderna/Merck), but with a specific focus on rapid, free, state-sponsored deployment in Russia. 

Conclusion: The Russian cancer vaccine projects (Enteromix) are in the early-to-intermediate stages of clinical development, showing promise in early trials, but require, and are currently undergoing, further validation to establish long-term safety and efficacy.